ViiV Healthcare
Presença
GSK é uma das ...
- Forbes Global 2000 (#187);
- Fortune 500 Europe (#81);
- FTSE 350;
- Global Fortune 500 (#343);
- Stoxx 600.
GSK é uma empresa listada sob o símbolo GSK (GB).
GSK tem presença direta em 21 países.GSK possui 22 subsidiárias incluindo GSK ANZ, GSK APAC e GSK Austria.
Fusão, aquisição e financiamento envolvendo GSK.
- GSK has announced the acquisition of Aiolos Bio (publicado em 12 de janeiro de 2024).
- GSK has announced the acquisition of Bellus Health (publicado em 19 de abril de 2023).
- GSK has announced the acquisition of Affinivax (publicado em 1 de junho de 2022).
Executivos
Veja o organograma con seus 22 executivos principais
Biografias mais buscadas da ViiV Healthcare
- Deborah Waterhouse, Chief Executive Officer and Director
- Regis Simard, Director
- David Redfern, Chairman of the Board
Recentes movimentos de executivos em GSK
- Jeannie Lee ingressará na Companhia como Non-Executive Director em 4 de mar. de 2024 (Notícia publicada em 29 de fevereiro de 2024).
- Wendy Becker ingressará na Companhia como Non-Executive Director em 1 de out. de 2023 (Notícia publicada em 28 de setembro de 2023).
Criar um alerta
para seguir os movimentos de executivos da ViiV Healthcare.
Farmacêutica
GSK possui 1.863 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
- Frontier Medicines acaba de anunciar uma arrecadação de fundos de 80 milhões de dólares. (publicado em 27 de fevereiro de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de ViiV Healthcare
- ViiV Healthcare announces new strategic alliance to enable greater access to antiretroviral medicines in Brazil
- ViiV Healthcare announces superior efficacy of investigational, long-acting injectable formulation of cabotegravir dosed every two months over daily oral PrEP
- ViiV Healthcare presents positive data from first-ever implementation research study on how best to integrate a investigational once-monthly injectable HIV treatment in US healthcare practices
- ViiV Healthcare shares new data from Positive Perspectives, Wave 2 study, confirming a more holistic approach to HIV care can improve quality of life
- ViiV Healthcare announces US FDA approval for Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available
- ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual)
- ViiV Healthcare announces grantees selected as part of £3 million Fund dedicated to HIV research and community-based programmes during COVID-19 pandemic
- Welsh Rugby star Gareth Thomas and ViiV Healthcare launch Tackle HIV campaign to address public misunderstanding and stigma associated with HIV
- Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP
- ViiV Healthcare announces £3 million global fund to research the impact of COVID-19 on the HIV community and fill gaps in prevention, treatment and care during the pandemic
- View more press releases Close
Redes sociais sobre ViiV Healthcare
- ViiV Healthcare na Wikipedia, Google News e Yahoo Finance
- ViiV Healthcare na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo David Redfern 
Ligue para a ViiV Healthcare em +44 792...
